MedTrace Logo

A Study on a Blood-based Dual-target Test for CRC Detection

NCT05508503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1378

Last updated 2024-02-16

No results posted yet for this study

Summary

To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.

Conditions

Interventions

DIAGNOSTIC_TEST

Test of methylated NTMT1 and MAP3K14-AS1

A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.

DIAGNOSTIC_TEST

FIT

Fecal immunochemical test（optional）

Sponsors & Collaborators

  • The Second Hospital of Hebei Medical University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaoshen Li, MD · Changhai Hospital, Navy/Second Military Medical University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-21
Primary Completion
2023-08-11
Completion
2023-08-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05508503 on ClinicalTrials.gov